Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 965-971

  Wynendaele, W ^a   Derua, R ^a   Hoylaerts, M F ^a   Pawinski, A ^a   Waelkens, E ^a   De Bruijn, E A ^a,b   Paridaens, R ^a   Merlevede, W ^a   Van Oosterom, A T ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Angiogenesis; Biological monitoring; Platelets; Vascular endothelial growth factor

Indexed keywords

ADENOSINE; ANGIOGENIC FACTOR; CITRATE SODIUM; CITRIC ACID; DIPYRIDAMOLE; EDETIC ACID; THEOPHYLLINE; THROMBOCYTE FACTOR 4; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BIOLOGICAL MONITORING; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PLASMA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ADULT; AGED; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032831462     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008377921886     Document Type: Article

References (46)

1. Dameron KM, Volpert OX Tainsky MA et al. Control of angiogenesis in flbroblasts by p53 regulation of throm-bospondin-1. Science 1994; 265: 1582-4.
2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. End Rev 1997; 18: 4-25.
3. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascots fluid. Science 1983; 219: 983-5.
4. Ferrara N, Henzel WJ. Pituitary follicular cells that secrete a novel heparin binding growth factor specific for endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-9.
5. Plouët J, Schilling J, Gospodarowics D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J 1989; 8: 3801-7.
6. Ferrara N, Houch K, Jakeman L et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrinol Rev 1992; 13: 19-32.
7. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellualar matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-26.
8. Senger DR, Peruzzi CA, Feder J et al. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986; 46: 5629-32.
9. Plate KH, Breier G, Weich HA et al. Vascular endothelial growth factor is a potent tumor angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
10. Berkman RA, Merrill MJ, Reinhold WC et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasm. J Clin Invest 1993; 91: 153-9.
11. Samoto K, Ikezaki K, Ono M et al. Expression of the vascular endothelial growth factor and its possible relation with neovascularistion in human brain tumors. Cancar Res 1995; 55: 1189-93.
12. Mattern J, Koomägi R, VoIm M. Association of vascular endothelial growth factor expression with intratumoral microvesel density and tumor cell proliferation in human epidermoïd lung cancer. Br J Cancer 1996; 73: 931-4.
13. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pretreatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998; 79: 144-6.
14. Brown LF, Berse B, Jackman RW et al. Expression of the vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
15. Brown LF, Berse B, Jackman RW et al. Increased expression of the vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255-62.
16. Takahashi A, Sasaki H, Kilm SJ et al. Markley increased amounts of messenger RNAs for vascular endothelial growth factor and placental growth factor in renal cell carcinomas associated with angiogenesis. Cancer Res 1994; 54: 4233-7.
17. Olson TA, Mohanraj D, Carson LF et al. Vascular permeability factor gene expression in normal and neoplastic ovaries. Cancer Res 1994; 54: 276-80.
18. Boocock CA, Charock-Jones DS, Sharkey AM et al. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-16.
19. Abu-Jawdeh GM, Faix JD, Niloff J et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996; 74: 1105-15.
20. Kondo S, Asano M, Matusuo K et al. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor bearing mice and cancer patients. Biochim Biophys Acta 1994; 1221: 211-4.
21. Yamamoto Y, Toi M, Kondo S et al. Concentrations of vascular endothelial growth factor in the sera of normal contols and cancer patients. Clin Cancer Res 1996; 2: 821-6.
22. Dirix LY, Vermeulen PB, Pawinski A et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in the sera of cancer patients. Br J Cancer 1997; 76: 238-43.
23. Salven P, Mäenpää H, Orpana A et al. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647-51.
24. Donovan D, Harmey JH, Toomey D et al. TGF-β-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997; 4: 611-2.
25. Heer K, Kumar H, Speirs et al. Preoperative serum VEGF in primary breast cancer patients - its relation with oestrogen receptor status and cancer type. Eur J Cancer 1998; 34 (Suppl 5): S29 (Abstr).
26. Fujisaki K, Mitsuyama K, Toyonaga A et al. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998; 93: 249-52.
27. Dirix LY, Vermeulen PB, Hubens G et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumor growth kinetics in advanced colorectal cancer. Ann Oncol 1996; 7: 843-8.
28. Yamamoto S., Konish L, Mandai M et al. Expression of vascular endithelial growth factor (VEGF) in epithelial ovarian neoplams: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997; 76: 1221-7.
29. Barton DP, Cau A, Wendt K et al. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res 1997; 3: 1579-86.
30. Ohira Y, Miura H, Tojo J et al. High serum levels of vascular endothelial growth factor in patients with human hepatocellular carcinoma. Hepatology Res 1997; 7: 13-8.
31. Salven P, Teerenhovi L, Joensuu H. A high pretreatment vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90: 3167-72.
32. Vermeulen PB, Dirix LY, Martin M et al. The predictive value of serum bFGF and VEGF in patients with metastatic renal cell carcinoma treated with interferon-2b. J Natl Cancer Inst 1997; 89: 1317.
33. Heits F, Katschinski DM, Wiedeman GJ et al. Serum vascular endothelial growth factor (VEGF), a prognostic indicator in sarcoma and carcinoma patients. Int J Oncol 1997; 10: 333-7.
34. Akiyoshi F, Sata M, Suzuki H et al. Serum vascular endothelial growth factor levels in various liver diseases. Dig Dis Sci 1998; 43: 41-5.
35. Lyall F, Greer IA, Boswell F et al. Suppression of serum vascular endothelial growth factor immunoreactivity in norman pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997; 104: 223-8.
36. Evans P, Wheeler T, Anthony F et al. Matenal serum vascular endothelial growth factor during early pregnancy. Clin Sci 1997; 92: 567-71.
37. Schürer-Maly CC, Fried M, Maly FE et al. Vascular endothelial growth factor in serum with inflammatory bowel disease. Scand J Gastroenterol 1997; 32: 959-60.
38. Banks RE, Forbes MA, Kinsey SE et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology. Br J Cancer 1998; 77: 956-64.
39. Möhle R, Green D, Moore MA et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 1997; 94: 663-8.
40. Verheul HM, Hoekman K, Luykx-de Bakker S et al. Platelet: Transporter of vascular endothelial growth factor. Clin Cancer Res 1998; 3: 2187-90.
41. Wynendaele W, Derua R, Hoylaerts MF et al. Vascular endothelial growth factor (VEGF): Plasma is the place to be. Ann Oncol 1998; 9 (Suppl 4): 122 (Abstr).
42. Freeman MR, Schneck FX, Gagnon ML et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140-5.
43. Berse B, Brown LF, van de Water L et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol Biol Cell 1992; 3: 211-20.
44. Wartiovaara U, Salven P, Mikkola H et al. Pheripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998; 80: 171-5.
45. Highley MS, de Bruijn EA. Erythrocytes and the transport of drugs and endogenous compounds. Pharmacol Res 1996; 13: 186-95.
46. de Vries EGE, Groen HJM, Wynendaele W et al. PNU-145156E - A novel angiogenesis inhibitor in patients with solid tumors: An update of a phase I and pharmacokenetic study. Proc ASCO 1999; 18: 161a.